Refocus Group, Inc. (RFCS)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Refocus Group, Inc. (RFCS) trades at $0.00 with AI Score 46/100 (Grade C). Refocus Group, Inc. is a medical device company focused on developing treatments for human vision disorders, primarily presbyopia. Market cap: $25, Sector: Healthcare.
Price live · AI analysis from Mar 18, 2026Analyst Coverage for RFCS: RFCS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RFCS against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RFCS: the 1 perspectives are evenly split.
How is this calculated? →Refocus Group, Inc. (RFCS) Healthcare & Pipeline Overview
Refocus Group, Inc., a medical device company founded in 1994, specializes in researching and developing treatments for vision disorders, with a focus on presbyopia. Their primary product, the VisAbility Micro-Insert System, is undergoing clinical trials, positioning them within the competitive medical device landscape targeting age-related vision correction.
What Is the Investment Thesis for RFCS?
Refocus Group, Inc. presents a high-risk, high-reward investment opportunity centered on the successful development and commercialization of its VisAbility Micro-Insert System. The company's value is primarily driven by the potential of this investigational medical device to address the large and growing market for presbyopia treatments. Successful completion of clinical trials and regulatory approval are critical milestones. Key risks include clinical trial failures, regulatory hurdles, limited financial resources, and competition from established players in the ophthalmology market. Investors should closely monitor clinical trial results, regulatory filings, and the company's ability to secure additional funding. The company's market capitalization of 25 reflects the speculative nature of the investment.
Based on FMP financials and quantitative analysis
RFCS Key Highlights
- Focus on Presbyopia Treatment: Addressing a significant market need with the VisAbility Micro-Insert System.
- Clinical Stage Development: Currently undergoing clinical trials, representing a key milestone for the company.
- Small Team: A lean team of 4 employees allows for focused operations but also presents resource constraints.
- Founded in 1994: Demonstrates a long-term commitment to vision correction research and development.
- Based in Dallas, Texas: Strategic location within a growing healthcare hub.
Who Are RFCS's Competitors?
RFCS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| AXGN AxoGen, Inc. | $45.08 | -1.77% | $2.40B | 58 |
| EW Edwards Lifesciences Corporation | $95.44 | +1.14% | $54.96B | 58 |
| OWLT Owlet, Inc. | $5.91 | +2.60% | $106.94M | 58 |
| CYBQY CYBERDYNE Inc. | $2.16 | +45.06% | $385.21M | 59 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RFCS's Key Strengths?
- Focus on a specific market niche (presbyopia treatment).
- Proprietary technology (VisAbility Micro-Insert System).
- Experienced management team in medical device development.
- Potential for significant market share in a growing market.
What Are RFCS's Weaknesses?
- Limited financial resources.
- Small team size.
- Dependence on a single product candidate.
- Lack of commercialization experience.
What Could Drive RFCS Stock Higher?
- Release of interim clinical trial results for the VisAbility Micro-Insert System.
- Submission of regulatory filings to the FDA for approval of the VisAbility Micro-Insert System.
- Continued enrollment of patients in clinical trials.
- Development of strategic partnerships with larger medical device companies.
- Progress in securing additional funding for research and development.
What Are the Key Risks for RFCS?
- Clinical trial failures could delay or halt the development of the VisAbility Micro-Insert System.
- Regulatory hurdles could prevent or delay the approval of the VisAbility Micro-Insert System.
- Competition from established players in the ophthalmology market could limit market share.
- Limited financial resources could constrain the company's ability to fund research and development.
- Dependence on a single product candidate exposes the company to significant risk.
What Are the Growth Opportunities for RFCS?
- Successful Clinical Trials: Positive results from ongoing clinical trials of the VisAbility Micro-Insert System are crucial for attracting investment and advancing the product towards regulatory approval. The global market for presbyopia correction is estimated to reach billions of dollars, offering a substantial opportunity for Refocus Group if the VisAbility Micro-Insert System proves effective and safe.
- Regulatory Approval: Securing regulatory approval from the FDA or other international regulatory bodies is essential for commercializing the VisAbility Micro-Insert System. This would open up access to key markets and allow the company to generate revenue. The timeline for regulatory approval depends on the clinical trial results and the regulatory review process, but typically takes several years.
- Strategic Partnerships: Forming strategic partnerships with larger medical device companies or pharmaceutical firms could provide Refocus Group with access to additional funding, expertise, and distribution channels. This could accelerate the commercialization of the VisAbility Micro-Insert System and expand its market reach. These partnerships could involve licensing agreements, joint ventures, or acquisitions.
- Expansion into New Markets: After establishing a presence in key markets such as the United States and Europe, Refocus Group could expand into emerging markets with growing populations and increasing demand for vision correction solutions. This would require adapting the VisAbility Micro-Insert System to local regulatory requirements and healthcare systems. The timeline for market expansion depends on the company's resources and strategic priorities.
- Development of New Products: Refocus Group could leverage its expertise in vision correction to develop new products and technologies targeting other vision disorders beyond presbyopia. This would diversify the company's product portfolio and reduce its reliance on the VisAbility Micro-Insert System. The timeline for new product development depends on the company's research and development capabilities and funding.
What Opportunities Does RFCS Have?
- Positive clinical trial results.
- Regulatory approval from the FDA.
- Strategic partnerships with larger companies.
- Expansion into new markets.
What Threats Does RFCS Face?
- Clinical trial failures.
- Regulatory hurdles.
- Competition from established players.
- Technological obsolescence.
What Are RFCS's Competitive Advantages?
- Patented Technology: The VisAbility Micro-Insert System is protected by patents, providing a barrier to entry for competitors.
- Clinical Data: Positive clinical trial results can create a competitive advantage by demonstrating the safety and efficacy of the device.
- Regulatory Approvals: Obtaining regulatory approvals from agencies like the FDA creates a significant barrier to entry for competitors.
- Specialized Expertise: Refocus Group's expertise in vision correction and medical device development provides a competitive advantage.
What Does RFCS Do?
Refocus Group, Inc., established in 1994 and based in Dallas, Texas, operates as a medical device company dedicated to the research and development of innovative treatments for human vision disorders. The company's primary focus is on addressing presbyopia, a common age-related vision condition that affects the ability to focus on near objects. Their lead product, the VisAbility Micro-Insert System, is an investigational medical device currently undergoing clinical trials. This system is designed for use in binocular presbyopic treatment, aiming to provide a surgical solution for patients seeking to improve their near vision. Refocus Group targets both patients and eye care professionals, positioning itself as a provider of advanced vision correction solutions. The company's operations are centered around the development, testing, and potential commercialization of the VisAbility Micro-Insert System, with the goal of establishing it as a viable treatment option within the ophthalmology market. The company's small size reflects its stage as a development-focused entity, prioritizing research and clinical trials over large-scale commercial operations.
What Products and Services Does RFCS Offer?
- Researches and develops treatments for human vision disorders.
- Focuses primarily on presbyopia, an age-related vision condition.
- Develops the VisAbility Micro-Insert System, an investigational medical device.
- Conducts clinical trials to evaluate the safety and efficacy of the VisAbility Micro-Insert System.
- Targets patients and eye care professionals with its vision correction solutions.
- Aims to provide a surgical solution for presbyopia.
How Does RFCS Make Money?
- Develops and patents medical devices for vision correction.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Aims to commercialize approved devices through direct sales or partnerships.
What Industry Does RFCS Operate In?
Refocus Group operates within the medical device industry, specifically targeting the ophthalmology market. The industry is characterized by technological innovation, stringent regulatory requirements, and intense competition. The market for presbyopia treatments is substantial and growing, driven by an aging global population. Key competitors include established medical device companies and pharmaceutical firms developing alternative treatments for vision disorders. Refocus Group's success depends on its ability to differentiate its VisAbility Micro-Insert System and navigate the complex regulatory landscape.
Who Are RFCS's Key Customers?
- Patients with presbyopia seeking vision correction.
- Eye care professionals (ophthalmologists and optometrists) who treat presbyopia.
- Hospitals and surgical centers that perform vision correction procedures.
Company Profile
Refocus Group, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Dallas, US. The company is led by CEO J. Michael Judy. RFCS has traded publicly since 2003.
RFCS Valuation & Market Position
Relative to its peer group, RFCS's quantitative score of 46/100 is below the peer average of 69/100.
RFCS Financials
Bull Case vs Bear Case
Bull Case
- Focus on a specific market niche (presbyopia treatment).
- Proprietary technology (VisAbility Micro-Insert System).
- Experienced management team in medical device development.
- Potential for significant market share in a growing market.
Bear Case
- Limited financial resources.
- Small team size.
- Dependence on a single product candidate.
- Lack of commercialization experience.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
RFCS Latest News
No recent news available for RFCS.
RFCS Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RFCS.
Price Targets
Wall Street price target analysis for RFCS.
RFCS MoonshotScore
What does this score mean?
The MoonshotScore rates RFCS's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: J. Michael Judy
Managing
J. Michael Judy serves as the managing leader of Refocus Group, Inc. His responsibilities encompass overseeing the company's strategic direction and the development of its VisAbility Micro-Insert System. Information regarding his prior career history, educational background, and specific credentials is not available in the provided data. His leadership is pivotal in guiding the company through its clinical trials and regulatory approval processes.
Track Record: Due to the limited information available, J. Michael Judy's specific achievements and strategic decisions at Refocus Group, Inc. cannot be comprehensively assessed. The company's current focus on clinical trials suggests his leadership is centered on advancing the VisAbility Micro-Insert System through the necessary regulatory pathways. His tenure is reflected in the company's ongoing efforts to bring its product to market.
RFCS OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Refocus Group, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, may be thinly traded, and are subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the lack of transparency and liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Liquidity: OTC stocks often have low trading volume, making it difficult to buy or sell shares.
- Lack of Transparency: OTC companies may have less stringent reporting requirements, making it harder to assess their financial health.
- Price Volatility: OTC stocks can be subject to significant price swings due to limited trading activity and speculative trading.
- Regulatory Scrutiny: OTC companies may face increased regulatory scrutiny due to their lower listing standards.
- Dilution Risk: OTC companies may be more likely to issue new shares to raise capital, diluting existing shareholders' ownership.
- Verify the company's registration and legal standing.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Understand the company's business model and competitive landscape.
- Evaluate the company's capital structure and funding needs.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Patents on the VisAbility Micro-Insert System.
- Ongoing clinical trials of the VisAbility Micro-Insert System.
- Company founded in 1994, indicating a long-term commitment.
- Focus on a specific market niche (presbyopia treatment).
- Company headquarters in Dallas, Texas.
RFCS Healthcare Stock FAQ
What does Refocus Group, Inc. do?
Refocus Group, Inc. is a medical device company specializing in the research and development of treatments for human vision disorders, primarily focusing on presbyopia. Their main product is the VisAbility Micro-Insert System, an investigational medical device designed for binocular presbyopic treatment. The company is currently conducting clinical trials to evaluate the safety and efficacy of this system, aiming to provide a surgical solution for patients seeking to improve their near vision and reduce reliance on reading glasses.
What do analysts say about RFCS stock?
As of 2026-03-18, there is no available analyst coverage for Refocus Group, Inc. (RFCS). The company's market capitalization of 25 reflects its early stage of development and the speculative nature of the investment. Investors should conduct their own thorough research and consider the risks associated with investing in small-cap, OTC-listed companies in the medical device industry. Key valuation metrics are not available due to the company's lack of revenue and earnings.
What are the main risks for RFCS?
The primary risks for Refocus Group, Inc. revolve around the successful development and commercialization of its VisAbility Micro-Insert System. Clinical trial failures, regulatory hurdles, and competition from established players in the ophthalmology market pose significant challenges. The company's limited financial resources and dependence on a single product candidate also increase its vulnerability. Furthermore, as an OTC-listed company, RFCS is subject to liquidity constraints and potential price volatility.
What are the key factors to evaluate for RFCS?
Refocus Group, Inc. (RFCS) holds an AI score of 46/100 (low). Not financial advice.
How frequently does RFCS data refresh on this page?
RFCS prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RFCS's recent stock price performance?
Refocus Group, Inc. (RFCS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on a specific market niche (presbyopia treatment). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RFCS overvalued or undervalued right now?
Valuing Refocus Group, Inc. (RFCS) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RFCS?
Before investing in Refocus Group, Inc. (RFCS), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on limited data available.
- AI analysis pending may provide further insights.